Advertisement
Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals Limited (PAR.AX) Stock Competitors & Peer Comparison

See (PAR.AX) competitors and their performances in Stock Market.

PAR.AXASX
HealthcareBiotechnology
$0.17
$0.005(2.94%)
Australian Market opens in 49h 1m
Advertisement

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
PAR.AXA$0.17+6.45%71.5M-2.26-A$0.07N/A
CSL.AXA$114.37-0.44%55.3B12.41A$9.30+3.69%
TLX.AXA$16.72+9.07%5.5B-583.54-A$0.03N/A
MSB.AXA$1.96+3.71%2.5B-13.11-A$0.15N/A
NEU.AXA$17.84+46.19%2.1B70.67A$0.23N/A
PYC.AXA$1.70+10.42%962M-36.18-A$0.05N/A
OPT.AXA$0.60+0.00%820.8M6.14A$0.10N/A
CUV.AXA$10.42+4.30%521.8M16.06A$0.64+0.48%
RAC.AXA$2.24+1.36%437.2M-107.73-A$0.02N/A
SPL.AXA$0.71+1.44%292.5M110.32A$0.01N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

PAR.AX vs CSL.AX Comparison July 2026

PAR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PAR.AX stands at 71.5M. In comparison, CSL.AX has a market cap of 55.3B. Regarding current trading prices, PAR.AX is priced at A$0.17, while CSL.AX trades at A$114.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PAR.AX currently has a P/E ratio of -2.26, whereas CSL.AX's P/E ratio is 12.41. In terms of profitability, PAR.AX's ROE is -2.66%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, PAR.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PAR.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions